🚀 VC round data is live in beta, check it out!
Selçuk Ecza Valuation Multiples
Discover revenue and EBITDA valuation multiples for Selçuk Ecza and similar public comparables like Yixintang Pharmaceutical, Anhui Huaren Health, Create SD Holdings, Aldawaa Medical Services and more.
Selçuk Ecza Overview
About Selçuk Ecza
Selcuk Ecza Deposu Ticaret ve Sanayi AS and its subsidiaries are in the business of export and import of drugs and patent medicines, medical supplies with pharmacy depot operations and also organize distribution channels between drug manufacturers, hospitals, and pharmacies. The company also distributes cosmetics, personal care, infant food, vitamins, medical and similar products.
Founded
1970
HQ
Employees
6.5K
Website
Sectors
Financials (LTM)
EV
$1B
Selçuk Ecza Financials
Selçuk Ecza reported last 12-month revenue of $4B and EBITDA of $119M.
In the same LTM period, Selçuk Ecza generated $395M in gross profit, $119M in EBITDA, and $32M in net income.
Revenue (LTM)
Selçuk Ecza P&L
In the most recent fiscal year, Selçuk Ecza reported revenue of $4B and EBITDA of $103M.
Selçuk Ecza expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $395M | XXX | $322M | XXX | XXX | XXX |
| Gross Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA | $119M | XXX | $103M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| EBIT Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $32M | XXX | $19M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 1% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Selçuk Ecza Stock Performance
Selçuk Ecza has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Selçuk Ecza's stock price is $2.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | (0.2%) | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSelçuk Ecza Valuation Multiples
Selçuk Ecza trades at 0.3x EV/Revenue multiple, and 9.0x EV/EBITDA.
EV / Revenue (LTM)
Selçuk Ecza Financial Valuation Multiples
As of March 7, 2026, Selçuk Ecza has market cap of $1B and EV of $1B.
Equity research analysts estimate Selçuk Ecza's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Selçuk Ecza has a P/E ratio of 39.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 0.3x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBIT | 9.7x | XXX | 11.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | 3.3x | XXX | XXX | XXX |
| P/E | 39.2x | XXX | 66.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 7.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Selçuk Ecza Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Selçuk Ecza Margins & Growth Rates
Selçuk Ecza's revenue in the last 12 month grew by 33%.
Selçuk Ecza's revenue per employee in the last FY averaged $0.6M.
Selçuk Ecza's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Selçuk Ecza's rule of X is 84% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Selçuk Ecza Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 36% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Growth | 71% | XXX | 87% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 84% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 6% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Selçuk Ecza Public Comps
See public comps and valuation multiples for other Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Yixintang Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Anhui Huaren Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Create SD Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Aldawaa Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| AiN Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Selçuk Ecza M&A Activity
Selçuk Ecza acquired XXX companies to date.
Last acquisition by Selçuk Ecza was on XXXXXXXX, XXXXX. Selçuk Ecza acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Selçuk Ecza
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSelçuk Ecza Investment Activity
Selçuk Ecza invested in XXX companies to date.
Selçuk Ecza made its latest investment on XXXXXXXX, XXXXX. Selçuk Ecza invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Selçuk Ecza
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Selçuk Ecza
| When was Selçuk Ecza founded? | Selçuk Ecza was founded in 1970. |
| Where is Selçuk Ecza headquartered? | Selçuk Ecza is headquartered in Turkey. |
| How many employees does Selçuk Ecza have? | As of today, Selçuk Ecza has over 6K employees. |
| Is Selçuk Ecza publicly listed? | Yes, Selçuk Ecza is a public company listed on Borsa Istanbul. |
| What is the stock symbol of Selçuk Ecza? | Selçuk Ecza trades under SELEC ticker. |
| When did Selçuk Ecza go public? | Selçuk Ecza went public in 2006. |
| Who are competitors of Selçuk Ecza? | Selçuk Ecza main competitors are Yixintang Pharmaceutical, Anhui Huaren Health, Create SD Holdings, Aldawaa Medical Services. |
| What is the current market cap of Selçuk Ecza? | Selçuk Ecza's current market cap is $1B. |
| What is the current revenue of Selçuk Ecza? | Selçuk Ecza's last 12 months revenue is $4B. |
| What is the current revenue growth of Selçuk Ecza? | Selçuk Ecza revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of Selçuk Ecza? | Current revenue multiple of Selçuk Ecza is 0.3x. |
| Is Selçuk Ecza profitable? | Yes, Selçuk Ecza is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Selçuk Ecza? | Selçuk Ecza's last 12 months EBITDA is $119M. |
| What is Selçuk Ecza's EBITDA margin? | Selçuk Ecza's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Selçuk Ecza? | Current EBITDA multiple of Selçuk Ecza is 9.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.